Zacks Investment Research upgraded Cidara Therapeutics Inc (NASDAQ:CDTX) to Hold in a report released today.
- Updated: October 17, 2016
Zacks Investment Research has upgraded Cidara Therapeutics Inc (NASDAQ:CDTX) to Hold in a report released on 10/17/2016.
Previously on Friday September 23, 2016, WBB Securities reported on Cidara Therapeutics Inc (NASDAQ:CDTX) raised the target price from $0.00 to $10.50. At the time, this indicated a possible downside of -0.14%.
Yesterday Cidara Therapeutics Inc (NASDAQ:CDTX) traded -0.10% lower at $9.91. Cidara Therapeutics Inc’s 50-day average is $11.23 and its two hundred day average is $11.72. With the last stock price down -15.44% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 39,793 shares of CDTX traded hands, down from an average trading volume of 57,097
Recent Performance Chart
Cidara Therapeutics Inc has 52 week low of $9.48 and a 52 week high of $18.07 and has a market capitalization of $0.
Brief Synopsis On Cidara Therapeutics Inc (NASDAQ:CDTX)
Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.